CBD: What Supplement Labels Won’t Tell You

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen. Dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

By TroupCoHealth.org Community Health Team | Last verified: July 2026

The Real Story

CBD (cannabidiol) has one FDA-approved use: as a prescription medication (Epidiolex) for rare seizure disorders. Beyond that narrow indication, the evidence for marketed CBD supplements is mixed, limited, and frequently contradicted by the claims on bottle labels. The supplement industry has built a $2+ billion market on preliminary animal research, small human studies, and marketing language that stretches minimal evidence into sweeping health promises. Most consumers are spending money on products that contain far less CBD than research suggests might be therapeutic—and often contain something different than what the label claims.

What It Is (Without the Marketing)

CBD is a non-intoxicating cannabinoid found in cannabis plants. Unlike THC, it does not produce a “high.” It is extracted from hemp (legally defined in the U.S. as cannabis with less than 0.3% THC) or cannabis with higher THC content. CBD works on multiple neurobiological systems: it may interact with serotonin receptors, vanilloid receptors, and the endocannabinoid system, though its exact mechanisms of action remain incompletely understood. It is metabolized primarily through the liver (CYP3A4 and CYP2C19 pathways), creating significant potential for drug interactions.

What the Marketing Claims

Supplement companies market CBD for anxiety, depression, pain, sleep, inflammation, cancer, seizures, Parkinson’s disease, heart health, and skin conditions. Wellness retailers and online sellers use language such as “natural anxiety relief,” “promotes calm,” “supports recovery,” “reduces inflammation,” and “improves sleep quality”—often with no scientific evidence whatsoever. Social media influencers and unverified testimonials amplify these claims. Many companies make illegal health claims (“treats anxiety disorder,” “cures insomnia”) that violate FDA regulations.

What the Research Actually Shows

The Evidence in Detail

Seizure Disorders (Epilepsy): This is the only condition where CBD has strong evidence and FDA approval. Epidiolex, a prescription CBD product, was approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome based on multiple randomized controlled trials showing seizure reduction. This is not a supplement claim—it is a pharmaceutical approval. Over-the-counter CBD products are not equivalent to Epidiolex in purity, dose, or efficacy.

Anxiety: A 2019 study published in The Permanente Journal involving 72 patients showed that 25 mg daily CBD may reduce anxiety scores. However, the study had methodological limitations, used different outcome measures, and involved a small sample. Animal studies show anxiolytic properties, but animal models do not reliably predict human response. Most human anxiety studies with CBD are observational or use non-standardized doses. A 2020 systematic review in Cannabis and Cannabinoid Research noted that “evidence remains preliminary and inconsistent across studies,” and most evidence comes from a single small sample or case reports.

Sleep: One small randomized trial (2019) showed marginal improvements in sleep with 160 mg CBD in participants with anxiety-related sleep issues—but it was difficult to separate CBD’s effect from anxiety reduction. Most sleep-related claims rely on testimonial evidence or animal studies. No large-scale human RCT exists for CBD and insomnia.

Pain: While preclinical evidence suggests CBD may interact with pain-modulation pathways, human clinical evidence is sparse. A 2020 review in Frontiers in Pharmacology concluded that “evidence for CBD in pain management remains limited, with most studies underpowered and using heterogeneous outcome measures.” Companies marketing CBD for fibromyalgia, arthritis, or chronic pain have essentially no human clinical support for these claims.

Inflammation, Depression, Cancer, and Other Conditions: Claims about CBD’s effects on inflammation, depression, cancer, heart health, or skin conditions are not supported by human clinical evidence. Animal studies and in vitro research do not translate reliably to human efficacy or safety. Marketing these products for these conditions violates FDA regulations on unauthorized health claims.

The Dose Problem

Consumer CBD supplements contain 10–1,500 mg per dose, but most range between 10–50 mg. Research suggesting benefit for anxiety used doses of 300–600 mg acutely, or 150–300 mg daily. Most off-the-shelf products deliver one-tenth to one-fifth of the doses used in supportive studies. Even at these low doses, consumers are typically paying $0.50–$2.00 per milligram of CBD, meaning a therapeutic trial (300+ mg daily) could cost $150–$600 per month.

Additionally, a 2020 analysis in JAMA found that 26–46% of CBD products are mislabeled, with actual CBD content differing significantly from label claims. Some products contained no detectable CBD. Without third-party lab testing (which most consumer products lack), buyers have no assurance of what they are purchasing.

What to Look For (and What to Avoid)

Red Flags in Products

• Proprietary blends: Any product listing CBD in a blend with other ingredients without disclosing individual amounts is non-transparent.
• Sub-therapeutic doses (<20 mg daily): Below the range used in supportive research; unlikely to be effective for claimed conditions.
• Unverified health claims: “Treats anxiety,” “cures insomnia,” “prevents cancer”—these are illegal claims unsupported by clinical evidence.
• No third-party testing: Products without verified lab reports showing CBD content and absence of contaminants (pesticides, heavy metals, THC) are unverifiable.
• Extremely low price: If a product claims high CBD content but costs significantly less than competitors, the labeled content is likely inflated.
• Vague sourcing: Companies that do not disclose whether hemp is U.S.-grown or imported, or that lack transparent extraction methods, may be cutting corners on quality.
• Claims of “full spectrum” superiority: Marketing suggesting full-spectrum CBD is inherently better than isolate lacks evidence. Both forms have the same supporting data.

What to Prefer

• Third-party lab testing (COAs—Certificates of Analysis) available on the company website.
• Clear labeling of milligrams per serving with transparent ingredient lists.
• Products from companies with published contact information and clear sourcing.
• Realistic marketing language that avoids health claims unsupported by the FDA.
• CBD isolate or broad-spectrum products if you want to avoid any THC exposure.

Safety Information

Drug Interactions

CBD inhibits the liver enzymes CYP3A4 and CYP2C19, which metabolize hundreds of medications. Significant interactions are possible with:

• Blood thinners (warfarin)
• Heart medications (some calcium channel blockers)
• Anti-seizure drugs (ironically, adding CBD to seizure medications requires careful medical supervision)
• Sedatives and sleep aids
• Statins
• Immunosuppressants
• Psychiatric medications (SSRIs, antipsychotics)

If you take any prescription medication, do not use CBD without consulting your healthcare provider or pharmacist.

Side Effects

Common reported side effects include fatigue, diarrhea, reduced appetite, and dry mouth. Some users report paradoxical anxiety at higher doses. Long-term safety data in humans are limited. Liver function abnormalities have been reported in some studies, particularly at high doses or with concurrent medications.

Who Should Avoid CBD

• Pregnant and breastfeeding women (insufficient safety data; animal studies show developmental concerns).
• People with liver disease (CBD is metabolized by the liver).
• Anyone taking medications metabolized by CYP3A4 or CYP2C19 without medical supervision.
• Children (unless prescribed Epidiolex for approved seizure disorders).
• Individuals with a history of psychosis or schizophrenia (high-dose CBD may increase psychiatric symptoms in susceptible individuals).
• People operating vehicles or machinery (CBD may cause drowsiness).

Bottom Line for Consumers

The evidence for CBD is genuine but narrow. If you have Dravet syndrome or Lennox-Gastaut syndrome, ask your neurologist about prescription Epidiolex—this is the only condition with solid clinical proof. For anxiety, emerging evidence suggests CBD may help, but the doses needed are much higher than most consumer products provide, and the effect size is modest compared to established treatments like therapy or SSRIs.

For sleep, pain, inflammation, depression, or cancer: the supplement industry’s marketing far outpaces the evidence. You are likely paying for a placebo effect or hoping that weak preclinical data will translate to you personally—and statistically, it probably will not.

If you decide to try CBD:

• Choose a product with third-party lab verification and transparent labeling.
• Expect to spend at least $100–$200 monthly for a dose range supported by research (300–600 mg daily).
• Check with your healthcare provider or pharmacist for drug interactions.
• Do not expect rapid or dramatic results; most supportive studies show modest effects over weeks to months.
• Have an exit plan: if CBD does not help within 4–6 weeks at an adequate dose, it likely will not help you.
• Do not replace evidence-based treatments (therapy, medication) with CBD while you “try” it

  Related Articles

  • SynergyRx Weight Loss: Integrating Telehealth GLP-1 Therapy...
  • Does Cbd Syrup Used As A Sleep Aid
  • Omega-3 — Consumer Research Brief
  • Semaglutide — Consumer Research Brief